Stonvex publishes market data and research only. Not investment advice. Not a registered investment advisor. Read disclaimer.

ZBIO

Live52w high -59.4%

Annual Quarterly

Core line items from ZBIO's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.

Log in Get Started

Annual Quarterly

Entity: Zenas BioPharma, Inc.·Source: SEC EDGAR companyfacts·Next-Q consensus from Finnhub

Metric	Q3 2026 (Est.) Expected 2026-08-10	Annual 2025 2025-12-31	Q3 2025 2025-09-30	Q2 2025 2025-06-30	Q1 2025 2025-03-31
Revenue	$0.00	$10.00M	$10.00M	$10.00M	$10.00M
Operating Income	Not available	$-383.06M	$-145.07M	$-92.49M	$-37.33M
Net Income	Not available	$-377.74M	$-137.29M	$-52.22M	$-33.57M
EPS (Diluted)	$-1.31	$-8.44	$-3.27	$-2.05	$-0.80
Total Assets	Not available	$383.64M	$322.02M	$293.08M	$333.77M
Total Liabilities	Not available	$141.50M	$125.59M	$53.46M	$49.45M
Cash & Equivalents	Not available	$110.64M	$115.56M	$44.01M	$196.55M
Free Cash Flow OCF − CapEx	Not available	$-172.35M	$-119.94M	$-78.81M	$-37.07M
Shares Outstanding	Not available	54.49M	42.21M	42.09M	41.82M

Financial data is sourced from public SEC filings where available. Some metrics may be unavailable without premium market data. The amber (Est.) column shows Wall Street analyst consensus for the next reporting period — only Revenue and EPS are covered by published consensus, so other line items remain blank. These are third-party estimates, not company guidance.

Core line items from ZBIO's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.

52w high -59.4%

Entity: Zenas BioPharma, Inc.·Source: SEC EDGAR companyfacts·Next-Q consensus from Finnhub

Metric	Q3 2026 (Est.) Expected 2026-08-10	Annual 2025 2025-12-31	Q3 2025 2025-09-30	Q2 2025 2025-06-30	Q1 2025 2025-03-31
Revenue	$0.00	$10.00M	$10.00M	$10.00M	$10.00M
Operating Income	Not available	$-383.06M	$-145.07M	$-92.49M	$-37.33M
Net Income	Not available	$-377.74M	$-137.29M	$-52.22M	$-33.57M
EPS (Diluted)	$-1.31	$-8.44	$-3.27	$-2.05	$-0.80
Total Assets	Not available	$383.64M	$322.02M	$293.08M	$333.77M
Total Liabilities	Not available	$141.50M	$125.59M	$53.46M	$49.45M
Cash & Equivalents	Not available	$110.64M	$115.56M	$44.01M	$196.55M
Free Cash Flow OCF − CapEx	Not available	$-172.35M	$-119.94M	$-78.81M	$-37.07M
Shares Outstanding	Not available	54.49M	42.21M	42.09M	41.82M

Financial data is sourced from public SEC filings where available. Some metrics may be unavailable without premium market data. The amber (Est.) column shows Wall Street analyst consensus for the next reporting period — only Revenue and EPS are covered by published consensus, so other line items remain blank. These are third-party estimates, not company guidance.